New Jersey-based Alpharma will provide development funding to India's Shasun Chemicals as part of a marketing pact to distribute generic drugs in the US and Europe. Shasun will manufacture 10 generic drugs for a variety of conditions -- including cardiovascular conditions -- with a cumulative market value of $20 billion.
- read this article [1] from the Business-Standard for more
Links:
[1] http://www.business-standard.com/bsonline/storypage.php?bKeyFlag=BO&autono=9720